|
|
 |
| GadoSpin™ F, MRI contrast agent |
|
| Description |
GadoSpin F is an amphiphilic gadolinium-based contrast agent with high protein-binding affinity specifically formulated for preclinical magnetic resonance imaging (MRI).
It is a contrast agent of high relaxivity increasing the signal intensity in T1-weighted MRI due to a shortening of the spin-lattice relaxation time (T1).
Upon intravenous injection, GadoSpin F rapidly binds to plasma proteins. This protein binding extends the residence time of the drug in the vascular space and, consequently, prolongs the imaging time window. Accumulation in atherosclerotic plaques can be observed allowing for direct visualization of plaque burden.
GadoSpin F is excreted in feces and urine. |
| Applications |
GadoSpin F is indicated for use in MRI of small animals, for example mice, to facilitate the visualization of the vasculature.
Examples include contrast-enhanced magnetic resonance angiography (MRA) and detection of atherosclerotic plaques. |
| Disclaimer |
For laboratory and animal research use only.
Warning: Not for human or animal therapeutic or diagnostic use.
Make sure to comply with all laws and regulations governing research on animals. |
| |
| Figure 1 |
| Schematic diagram of GadoSpin™ F. |
 |
|
| Figure 2 |
| Accumulation of GadoSpin F in WHHL rabbit atherosclerotic plaque as measured by T1- weighted MRI (TFL IR, 1.5T) 6 and 24 hours after injection. |
 |
 |
|
|
|
|
| Favorites / Prices |
Request prices or add products to your favorite list.
|
| Details |
|
| Products |
| GadoSpin F |
- 5 injections (1)
Components
- 1 vial
Download datasheet
130-095-162
|
- 25 injections (1)
Components
- 5 vials
Download datasheet
130-095-163
|
| (1) One vial contains 850 μL of imaging agent, sufficient for 5 injections of the recommended volume of 100 μL (for a 20–30 g mouse). |
|
| References |
| 1. Zheng, J. et al. (2008) Invest. Radiol. 43: 49-55. |
| 2. Raatschen, H. J. et al. (2006) Contrast Media Mol. Imaging 1: 113-120. |
| 3. Barkhausen, J. et al. (2003) Circulation 108: 605-609. |
|
|
|
© 1999 - 2012 Miltenyi Biotec ¦ Terms & conditions ¦ Legal notes
|
